Skip to main content
Literatur
2.
Zurück zum Zitat Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23. CrossRefPubMed Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23. CrossRefPubMed
3.
Zurück zum Zitat Verheijen RH, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol. 2006;24(4):571–8. CrossRefPubMed Verheijen RH, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol. 2006;24(4):571–8. CrossRefPubMed
4.
Zurück zum Zitat Bodei L, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5–19. CrossRefPubMed Bodei L, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5–19. CrossRefPubMed
5.
Zurück zum Zitat Del Prete M, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46(3):728–42. CrossRefPubMed Del Prete M, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46(3):728–42. CrossRefPubMed
6.
Zurück zum Zitat Pouget JP, et al. Introduction to radiobiology of targeted radionuclide therapy. Front Med. 2015;2:12. CrossRef Pouget JP, et al. Introduction to radiobiology of targeted radionuclide therapy. Front Med. 2015;2:12. CrossRef
7.
Zurück zum Zitat European Association of Nuclear Medicine Internal Dosimetry Task Force Report, Treatment planning for molecular radiotherapy: potential and prospects. Flux G, Stokke C., editors. 2017. European Association of Nuclear Medicine Internal Dosimetry Task Force Report, Treatment planning for molecular radiotherapy: potential and prospects. Flux G, Stokke C., editors. 2017.
8.
Zurück zum Zitat European Council Directive. 2013/59/Euratom of 5 December 2013 laying down basic safety standards for protections against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. Off J Eur Union. 2014. European Council Directive. 2013/59/Euratom of 5 December 2013 laying down basic safety standards for protections against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. Off J Eur Union. 2014.
10.
Metadaten
Titel
Call to arms: need for radiobiology in molecular radionuclide therapy
verfasst von
Samantha Y. A. Terry
Julie Nonnekens
An Aerts
Sarah Baatout
Marion de Jong
Bart Cornelissen
Jean-Pierre Pouget
Publikationsdatum
08.05.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04334-3

Weitere Artikel der Ausgabe 8/2019

European Journal of Nuclear Medicine and Molecular Imaging 8/2019 Zur Ausgabe

Letter to the Editor

Reply to the letter